Table 1.

Clinical and laboratory characteristics including amino acid measurements of 9548 participants at the baseline study of the METSIM cohort

VariablesNo CVD (N = 8578)CAD (N = 666)Stroke (N = 394)CVD (N = 970)
Age, y57.0 ± 7.060.6 ± 6.7a61.8 ± 6.7a60.8 ± 6.8a
Type 2 diabetes, % of total5.914.0a15.2a13.3a
Current smokers, % of total17.624.9a20.123.5a
Medication for hypertension, %19.331.0a30.7a29.6a
Body mass index, kg/m227.2 ± 4.128.2 ± 4.5a27.9 ± 4.628.0 ± 4.5a
Waist, cm98.4 ± 11.4101.7 ± 12.3a100.9 ± 12.0a101.17 ± 12.1a
Systolic blood pressure, mmHg137.6 ± 16.4143.5 ± 18.0a144.0 ± 19.1a143.5 ± 18.2a
Diastolic blood pressure, mmHg87.4 ± 9.388.3 ± 10.587.5 ± 10.288.25 ± 10.4
HDL cholesterol, mmol/L1.45 ± 0.391.36 ± 0.39a1.40 ± 0.401.38 ± 0.40a
LDL cholesterol, mmol/L3.36 ± 0.883.38 ± 0.943.25 ± 0.993.36 ± 0.94
Total triglycerides, mmol/L1.44 ± 0.871.70 ± 1.17a1.51 ± 0.881.60 ± 1.03a
Blood HbA1c, %5.8 ± 0.66.0 ± 0.8a6.0 ± 0.7a6.0 ± 0.8a
Fasting plasma glucose, mmol/L5.92 ± 0.986.27 ± 1.57a6.17 ± 1.31a6.19 ± 1.42a
2-h plasma glucose, mmol/L6.37 ± 2.347.04 ± 2.88a7.05 ± 2.69a6.96 ± 2.75a
Fasting plasma insulin, mU/L9.2 ± 9.113.4 ± 24.9a12.5 ± 19.8a12.4 ± 21.7a
2-hour plasma insulin, mU/L53.9 ± 56.766.6 ± 64.6a65.0 ± 59.3a64.2 ± 60.6a
C-reactive protein, mg/L2.07 ± 4.192.75 ± 4.18a3.16 ± 5.58a2.90 ± 4.87a
Alanine (mmol/L)0.416 ± 0.0640.433 ± 0.066a0.428 ± 0.0640.429 ± 0.065a
Glutamine (mmol/L)0.514 ± 0.0750.502 ± 0.073a0.499 ± 0.0750.502 ± 0.074a
Glycine (mmol/L)0.277 ± 0.0710.279 ± 0.0720.278 ± 0.0760.279 ± 0.075
Histidine (mmol/L)0.064 ± 0.0090.063 ± 0.0090.062 ± 0.009a0.063 ± 0.009a
Isoleucine (mmol/L)0.060 ± 0.0170.064 ± 0.019a0.062 ± 0.0170.063 ± 0.018a
Leucine (mmol/L)0.090 ± 0.0170.093 ± 0.02a0.091 ± 0.0170.092 ± 0.019a
Phenylalanine (mmol/L)0.075 ± 0.0120.080 ± 0.012a0.080 ± 0.014a0.080 ± 0.013a
Tyrosine (mmol/L)0.057 ± 0.0120.060 ± 0.012a0.059 ± 0.0110.059 ± 0.012a
Valine (mmol/L)0.217 ± 0.0370.221 ± 0.040.220 ± 0.0370.220 ± 0.038
VariablesNo CVD (N = 8578)CAD (N = 666)Stroke (N = 394)CVD (N = 970)
Age, y57.0 ± 7.060.6 ± 6.7a61.8 ± 6.7a60.8 ± 6.8a
Type 2 diabetes, % of total5.914.0a15.2a13.3a
Current smokers, % of total17.624.9a20.123.5a
Medication for hypertension, %19.331.0a30.7a29.6a
Body mass index, kg/m227.2 ± 4.128.2 ± 4.5a27.9 ± 4.628.0 ± 4.5a
Waist, cm98.4 ± 11.4101.7 ± 12.3a100.9 ± 12.0a101.17 ± 12.1a
Systolic blood pressure, mmHg137.6 ± 16.4143.5 ± 18.0a144.0 ± 19.1a143.5 ± 18.2a
Diastolic blood pressure, mmHg87.4 ± 9.388.3 ± 10.587.5 ± 10.288.25 ± 10.4
HDL cholesterol, mmol/L1.45 ± 0.391.36 ± 0.39a1.40 ± 0.401.38 ± 0.40a
LDL cholesterol, mmol/L3.36 ± 0.883.38 ± 0.943.25 ± 0.993.36 ± 0.94
Total triglycerides, mmol/L1.44 ± 0.871.70 ± 1.17a1.51 ± 0.881.60 ± 1.03a
Blood HbA1c, %5.8 ± 0.66.0 ± 0.8a6.0 ± 0.7a6.0 ± 0.8a
Fasting plasma glucose, mmol/L5.92 ± 0.986.27 ± 1.57a6.17 ± 1.31a6.19 ± 1.42a
2-h plasma glucose, mmol/L6.37 ± 2.347.04 ± 2.88a7.05 ± 2.69a6.96 ± 2.75a
Fasting plasma insulin, mU/L9.2 ± 9.113.4 ± 24.9a12.5 ± 19.8a12.4 ± 21.7a
2-hour plasma insulin, mU/L53.9 ± 56.766.6 ± 64.6a65.0 ± 59.3a64.2 ± 60.6a
C-reactive protein, mg/L2.07 ± 4.192.75 ± 4.18a3.16 ± 5.58a2.90 ± 4.87a
Alanine (mmol/L)0.416 ± 0.0640.433 ± 0.066a0.428 ± 0.0640.429 ± 0.065a
Glutamine (mmol/L)0.514 ± 0.0750.502 ± 0.073a0.499 ± 0.0750.502 ± 0.074a
Glycine (mmol/L)0.277 ± 0.0710.279 ± 0.0720.278 ± 0.0760.279 ± 0.075
Histidine (mmol/L)0.064 ± 0.0090.063 ± 0.0090.062 ± 0.009a0.063 ± 0.009a
Isoleucine (mmol/L)0.060 ± 0.0170.064 ± 0.019a0.062 ± 0.0170.063 ± 0.018a
Leucine (mmol/L)0.090 ± 0.0170.093 ± 0.02a0.091 ± 0.0170.092 ± 0.019a
Phenylalanine (mmol/L)0.075 ± 0.0120.080 ± 0.012a0.080 ± 0.014a0.080 ± 0.013a
Tyrosine (mmol/L)0.057 ± 0.0120.060 ± 0.012a0.059 ± 0.0110.059 ± 0.012a
Valine (mmol/L)0.217 ± 0.0370.221 ± 0.040.220 ± 0.0370.220 ± 0.038

Values shown as mean ± SD for each category.

Abbreviations: CAD, coronary artery disease; CVD, cardiovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; METSIM, Metabolic Syndrome in Men.

aStatistically significant differences (P < 0.002) between CAD, stroke, and CVD and control group (no CVD).

Table 1.

Clinical and laboratory characteristics including amino acid measurements of 9548 participants at the baseline study of the METSIM cohort

VariablesNo CVD (N = 8578)CAD (N = 666)Stroke (N = 394)CVD (N = 970)
Age, y57.0 ± 7.060.6 ± 6.7a61.8 ± 6.7a60.8 ± 6.8a
Type 2 diabetes, % of total5.914.0a15.2a13.3a
Current smokers, % of total17.624.9a20.123.5a
Medication for hypertension, %19.331.0a30.7a29.6a
Body mass index, kg/m227.2 ± 4.128.2 ± 4.5a27.9 ± 4.628.0 ± 4.5a
Waist, cm98.4 ± 11.4101.7 ± 12.3a100.9 ± 12.0a101.17 ± 12.1a
Systolic blood pressure, mmHg137.6 ± 16.4143.5 ± 18.0a144.0 ± 19.1a143.5 ± 18.2a
Diastolic blood pressure, mmHg87.4 ± 9.388.3 ± 10.587.5 ± 10.288.25 ± 10.4
HDL cholesterol, mmol/L1.45 ± 0.391.36 ± 0.39a1.40 ± 0.401.38 ± 0.40a
LDL cholesterol, mmol/L3.36 ± 0.883.38 ± 0.943.25 ± 0.993.36 ± 0.94
Total triglycerides, mmol/L1.44 ± 0.871.70 ± 1.17a1.51 ± 0.881.60 ± 1.03a
Blood HbA1c, %5.8 ± 0.66.0 ± 0.8a6.0 ± 0.7a6.0 ± 0.8a
Fasting plasma glucose, mmol/L5.92 ± 0.986.27 ± 1.57a6.17 ± 1.31a6.19 ± 1.42a
2-h plasma glucose, mmol/L6.37 ± 2.347.04 ± 2.88a7.05 ± 2.69a6.96 ± 2.75a
Fasting plasma insulin, mU/L9.2 ± 9.113.4 ± 24.9a12.5 ± 19.8a12.4 ± 21.7a
2-hour plasma insulin, mU/L53.9 ± 56.766.6 ± 64.6a65.0 ± 59.3a64.2 ± 60.6a
C-reactive protein, mg/L2.07 ± 4.192.75 ± 4.18a3.16 ± 5.58a2.90 ± 4.87a
Alanine (mmol/L)0.416 ± 0.0640.433 ± 0.066a0.428 ± 0.0640.429 ± 0.065a
Glutamine (mmol/L)0.514 ± 0.0750.502 ± 0.073a0.499 ± 0.0750.502 ± 0.074a
Glycine (mmol/L)0.277 ± 0.0710.279 ± 0.0720.278 ± 0.0760.279 ± 0.075
Histidine (mmol/L)0.064 ± 0.0090.063 ± 0.0090.062 ± 0.009a0.063 ± 0.009a
Isoleucine (mmol/L)0.060 ± 0.0170.064 ± 0.019a0.062 ± 0.0170.063 ± 0.018a
Leucine (mmol/L)0.090 ± 0.0170.093 ± 0.02a0.091 ± 0.0170.092 ± 0.019a
Phenylalanine (mmol/L)0.075 ± 0.0120.080 ± 0.012a0.080 ± 0.014a0.080 ± 0.013a
Tyrosine (mmol/L)0.057 ± 0.0120.060 ± 0.012a0.059 ± 0.0110.059 ± 0.012a
Valine (mmol/L)0.217 ± 0.0370.221 ± 0.040.220 ± 0.0370.220 ± 0.038
VariablesNo CVD (N = 8578)CAD (N = 666)Stroke (N = 394)CVD (N = 970)
Age, y57.0 ± 7.060.6 ± 6.7a61.8 ± 6.7a60.8 ± 6.8a
Type 2 diabetes, % of total5.914.0a15.2a13.3a
Current smokers, % of total17.624.9a20.123.5a
Medication for hypertension, %19.331.0a30.7a29.6a
Body mass index, kg/m227.2 ± 4.128.2 ± 4.5a27.9 ± 4.628.0 ± 4.5a
Waist, cm98.4 ± 11.4101.7 ± 12.3a100.9 ± 12.0a101.17 ± 12.1a
Systolic blood pressure, mmHg137.6 ± 16.4143.5 ± 18.0a144.0 ± 19.1a143.5 ± 18.2a
Diastolic blood pressure, mmHg87.4 ± 9.388.3 ± 10.587.5 ± 10.288.25 ± 10.4
HDL cholesterol, mmol/L1.45 ± 0.391.36 ± 0.39a1.40 ± 0.401.38 ± 0.40a
LDL cholesterol, mmol/L3.36 ± 0.883.38 ± 0.943.25 ± 0.993.36 ± 0.94
Total triglycerides, mmol/L1.44 ± 0.871.70 ± 1.17a1.51 ± 0.881.60 ± 1.03a
Blood HbA1c, %5.8 ± 0.66.0 ± 0.8a6.0 ± 0.7a6.0 ± 0.8a
Fasting plasma glucose, mmol/L5.92 ± 0.986.27 ± 1.57a6.17 ± 1.31a6.19 ± 1.42a
2-h plasma glucose, mmol/L6.37 ± 2.347.04 ± 2.88a7.05 ± 2.69a6.96 ± 2.75a
Fasting plasma insulin, mU/L9.2 ± 9.113.4 ± 24.9a12.5 ± 19.8a12.4 ± 21.7a
2-hour plasma insulin, mU/L53.9 ± 56.766.6 ± 64.6a65.0 ± 59.3a64.2 ± 60.6a
C-reactive protein, mg/L2.07 ± 4.192.75 ± 4.18a3.16 ± 5.58a2.90 ± 4.87a
Alanine (mmol/L)0.416 ± 0.0640.433 ± 0.066a0.428 ± 0.0640.429 ± 0.065a
Glutamine (mmol/L)0.514 ± 0.0750.502 ± 0.073a0.499 ± 0.0750.502 ± 0.074a
Glycine (mmol/L)0.277 ± 0.0710.279 ± 0.0720.278 ± 0.0760.279 ± 0.075
Histidine (mmol/L)0.064 ± 0.0090.063 ± 0.0090.062 ± 0.009a0.063 ± 0.009a
Isoleucine (mmol/L)0.060 ± 0.0170.064 ± 0.019a0.062 ± 0.0170.063 ± 0.018a
Leucine (mmol/L)0.090 ± 0.0170.093 ± 0.02a0.091 ± 0.0170.092 ± 0.019a
Phenylalanine (mmol/L)0.075 ± 0.0120.080 ± 0.012a0.080 ± 0.014a0.080 ± 0.013a
Tyrosine (mmol/L)0.057 ± 0.0120.060 ± 0.012a0.059 ± 0.0110.059 ± 0.012a
Valine (mmol/L)0.217 ± 0.0370.221 ± 0.040.220 ± 0.0370.220 ± 0.038

Values shown as mean ± SD for each category.

Abbreviations: CAD, coronary artery disease; CVD, cardiovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; METSIM, Metabolic Syndrome in Men.

aStatistically significant differences (P < 0.002) between CAD, stroke, and CVD and control group (no CVD).

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close